Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for Hereditary Ataxia
NCT01360164Phase 2Unknown
- Sponsor
- Beike Biotechnology
- Start
- Jan 2010
- Primary completion
- Dec 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in hereditary ataxia, sponsored by Beike Biotechnology. Primary endpoints: International Cooperative Ataxia Rating Scale at 1 year, Berg Balance Scale at 1 year and 1 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
hereditary ataxia
Beyond the preview
Go deeper on NCT01360164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360164.